Journal Mobile Options
Table of Contents
Vol. 84, No. 2, 2010
Issue release date: March 2010
Urol Int 2010;84:159–163
(DOI:10.1159/000277592)

Prognostic Factors Affecting Progression and Survival in Metastatic Prostate Cancer

Nayyar R. · Sharma N. · Gupta N.P.
Department of Urology, All India Institute of Medical Sciences, New Delhi, India

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Purpose: To evaluate the role of age, Gleason score, prostate-specific antigen (PSA), PSA doubling time (PSADT), and PSA half-time (PSAT1/2) as prognostic factors in metastatic prostate cancer to predict long-term outcome. Patients and Methods: 412 patients with metastatic prostate cancer diagnosed after January 1995, with at least 6 months of follow-up, were enrolled. Serum PSA was determined at diagnosis and every 3–6 months thereafter. All patients underwent medical or surgical castration. End points of the study were either death or disease progression. Univariate and multivariate Cox proportional hazard analysis was used to evaluate prognostic factors. Results: Median progression-free and overall survival was 3 and 5.7 years. Patients aged ≤65 years at diagnosis, high baseline PSA and high nadir PSA were associated with poor overall survival. Patients with a PSAT1/2 of <6 months, high baseline alkaline phosphatase, and PSADT of <1 month had significantly poorer progression-free and overall survival. Conclusion: Prostate cancer is a common malignancy in the elderly population. We have found that younger patients with high baseline and nadir PSA, shorter PSADT and PSAT1/2 have poorer overall and progression-free survival.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Prostate Cancer Trialists’ Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491–1498.
  2. Aus G, Robinson D, Rossel J, Sandblom G, Varenhorst E: Survival in prostate cancer – outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer registry of Sweden. Cancer 2005;103:943–951.
  3. Ernst DS, Hanson J, Venner PM: Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. J Urol 1991;146:372–376.
  4. Ishikawa S, Soloway MS, Van der Zwaag R, Todd B: Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989;141:1139–1142.
  5. Mulders PFA, Dijkman GA, Fernandez del Moral P, Theeuwes AGM, Debruyne FMJ: Analysis of prognostic factors in disseminated prostate cancer. An update. Dutch Southeastern Urological Cooperative Group. Cancer 1990;65:2758–2761.
  6. Kreis W, Ahmann FR, Lesser M, Scott M, Caplan R, Gau T, Vinciguerra V: Predictive initial parameters for response of stage D prostate cancer to treatment with the luteinizing hormone-releasing hormone agonist goserelin. J Clin Oncol 1990;8:870–874.
  7. Johansson JE, Andersson SO, Holmberg L, Bergström R: Prognostic factors in progression-free survival and corrected survival in patients with advanced prostate cancer. Results from a randomized study comprising 150 patients treated with orchiectomy or estrogens. J Urol 1991;146:1327–1332.
  8. de Vogt HJ, Suciu S, Sylvester R, Pavone-Macaluso M, Smith PH, de Pauw M: Multivariate analysis of prognostic factors in patients with advanced prostate cancer: results from two European Organization for Research on Treatment of Cancer trials. J Urol 1989;141:883–888.

    External Resources

  9. Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS, Epstein JI: Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease free survival among patients with prostate cancer. Cancer 1992;70:161–168.
  10. Reijke TM, Derobert E: Prognostic factors analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. Eur Urol 2002;42:139–146.
  11. Sengupta S, Myers RP, Slezak JM, et al: Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005;174:2191–2196.
  12. Kuriyama M, Akimoto S, Akaza H, et al: Comparison of various assay systems for prostate specific antigen standardization. Jpn J Clin Oncol 1992;22:393–399.
  13. Daskivich TJ, Regan MM, Oh WK: Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. Urology 2007;70:527–531.
  14. Reynard JM, Peters TJ, Gillatt D: Prostate-specific antigen and prognosis in patients with metastatic prostate cancer – a multivariate analysis of prostate cancer mortality. Br J Urol 1995;75:507–515.
  15. Cooper EH, Armitage TG, Robinson MRG, Newling DW, Richards BR, Smith PH, Denis L, Sylvester R: Prostate specific antigen and the prediction of prognosis in metastatic prostate cancer. Cancer 1990;66:1025–1028.
  16. Osterlinck W, Mattelaer J, Casselman J, Van Velthoven R, Derde MP, Kaufmann L: PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients. Acta Urol Belg 1997;65:63–71.
  17. Collette L, de Reijke TM, Schröder FH, EORTC Genito-Urinary Group: Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 2003;44:182–189.
  18. Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D: Validation of surrogate end points in multiple randomized clinical trials with failure-time endpoints. Appl Stat 2001;50:405–422.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50